Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncogene. 2015 Mar 5;34(10):1207-19. doi: 10.1038/onc.2014.43. Epub 2014 Mar 31.

B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway.

Author information

  • 1Graduate Institute of Oral Biology, School of Dentistry, National Taiwan University, Taipei, Taiwan.
  • 2Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.
  • 3Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
  • 41] Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan [2] Department of Pediatrics, National Taiwan University Hospital YunLin Branch, Taipei, Taiwan.
  • 5Department of Dentistry and Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan.
  • 61] Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan [2] Department of Physical Medicine and Rehabilitation, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
  • 7Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.

Abstract

B-cell lymphoma/leukemia 10 (BCL10) is an apoptotic regulatory protein related to advanced TNM stage and disease recurrence in oral squamous cell carcinoma (OSCC). However, the regulatory mechanism of BCL10 in OSCC progression is still unknown. Here, we showed that knockdown of endogenous BCL10 could significantly reduce cell migration and invasion abilities, retard cell proliferation by G0/G1 phase accumulation and inhibit tumorigenicity in vivo. In molecular level, we identified S100P as a crucial downstream effector of BCL10-inhibited OSCC progression by high-throughput microarray analysis. S100P messenger RNA and protein expression levels were significantly diminished in silenced-BCL10 clones, and transfected S100P expression plasmids restored migration, invasion, proliferation abilities and tumorigenicity in shBCL10 transfectants. Furthermore, we provided evidence that BCL10 regulated S100P expression through signal transducers and activators of transcription 1 (STAT1) and activating transcription factor 4 (ATF4). Knockdown of BCL10 decreased S100P promoter activity, but showed no effect in truncated STAT1/ATF4 S100P promoter.  In addition, we also found that the P50/P65 signaling pathway was involved in BCL10-enhanced OSCC progression. Restored S100P in silenced-BCL10 clones could markedly reverse P65 activation via outside-in signaling. Taken together, we discovered a novel axis of BCL10-regulated OSCC progression via STAT1/ATF4/S100P/P65 signaling, which could predict the prognosis of OSCC and will be beneficial for developing therapeutic strategy against advanced OSCC.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk